Loading...

China's iKang announces acquisition of INLUNG

Image

22-Dec-15 iKang Healthcare Group, China's largest private preventive healthcare provider, announced it has acquired 70% interest of Xi'an iKang Health Management, which owns three medical centers under the brand name Xi'an INLUNG. This marks iKang's first steps into Xi'an, capital of Shaanxi Province. [image: Sapphire Healthcare]

Read More

AstraZeneca investing USD800 mn to go local in China

Image

16-Dec-15 AstraZeneca aims to build up its already strong position in China by making and developing more medicines locally, and will invest more than USD800 mn in the country over the next 10 years. The British drugmaker's decision to step up investment, notably through a strategic alliance with WuXi AppTec, chimes with Beijing's desire to see more treatments made in China. [image: China Daily]

Read More

Chinese consumers spend USD10 bn on health on Alibaba

Image

14-Dec-15 Chinese consumers spent RMB65 bn (USD10 bn) buying medicines, healthcare products and services on Alibaba’s Chinese retail sites in 2014, up 63% from a year earlier. In addition, sales of nursing care services grew 205% on Singles’ Day, while sales of health insurance increased 432% on Alibaba’s sites, including the huge Taobao and Tmall marketplaces. [image: International Supermarket News]

Read More

Here's why East Asia could be in big trouble

Image

09-Dec-15 Many countries in East Asia now have to worry about losing as much as 15% of their working-age population by 2040, according to the World Bank. It said aging population and low fertility rates are to blame. Policies such as encouraging women to work, reforming pension schemes and shifting focus from hospital care to primary care are being recommended. [image: Zhang Peng / LightRocket / Getty Images]

Read More

China's reforms will hurt US manufacturers

Image

08-Dec-15 China's implementation of healthcare reforms, changing the approval process for new medical devices and favoring local manufacturers will restrain growth for US medical manufacturers, says Moody's. China's healthcare reforms will be particularly credit negative for companies that make complex devices, such as Medtronic, Boston Scientific and St Jude. [image: Shannon Stapleton / Reuters]

Read More
Share